MINERALYS THERAPEUTICS INC (MLYS)
US6031701013 - Common Stock
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ: MLYS)....
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ: MLYS)....
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ: MLYS)....
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ: MLYS)....
Mineralys Therapeutics Becomes Oversold (MLYS)
MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q2 2024
MLYS stock results show that Mineralys Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mineralys Therapeutics (NASDAQ:MLYS) just reported results for the second quart...
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – – Enrollment ahead of schedule in Phase 3...
Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024...
Commit To Buy Mineralys Therapeutics At $10, Earn 19.5% Annualized Using Options
MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q1 2024
MLYS stock results show that Mineralys Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 – – Ongoing Phase 3 pivotal...
Mineralys Therapeutics Breaks Below 200-Day Moving Average - Notable for MLYS
Commit To Buy Mineralys Therapeutics At $7.50, Earn 13.2% Annualized Using Options
Mineralys Therapeutics Enters Oversold Territory (MLYS)
MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023
MLYS stock results show that Mineralys Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mineralys Therapeutics (NASDAQ:MLYS) just reported results for the fourth quart...
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
– Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in...
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on...
Commit To Purchase Mineralys Therapeutics At $12.50, Earn 45.9% Annualized Using Options
Mineralys Therapeutics stock jumps on $120M private placement financing (NASDAQ:MLYS)
Mineralys Therapeutics secures $120M in private placement financing through the sale of common shares, led by TCGX and RA Capital Management.
Mineralys Therapeutics Announces $120 Million Private Placement Financing
RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on...
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on...
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on...
Mineralys stock jumps 13% after first patient dosed in hypertension study (NASDAQ:MLYS)
Mineralys (MLYS) stock gained 13% following news that the first patient had been dosed in a pivotal study for its hypertension drug candidate lorundrostat. Read more here.
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 – ...
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity,...
Mineralys Therapeutics GAAP EPS of -$0.57 (NASDAQ:MLYS)
Mineralys Therapeutics press release (NASDAQ:MLYS): Q3 GAAP EPS of -$0.57.Cash, cash equivalents and investments were $265.9 million as of September 30,...
Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in...
Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023
RADNOR, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on...
Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023
Late-breaking poster presentation at ASN’s Kidney Week 2023 - - -Poster presentation at AHA’s Scientific Sessions 2023 RADNOR, Pa., Oct. 13, 2023 (GLOBE...